AAAAAA

   
Results: 1-9 |
Results: 9
Pretargeted radioimmunotherapy (PRIT (TM)) for treatment of non-Hodgkin's lymphoma (NHL)
Authors: Weiden, PL Breitz, HB
Citation: Pl. Weiden et Hb. Breitz, Pretargeted radioimmunotherapy (PRIT (TM)) for treatment of non-Hodgkin's lymphoma (NHL), CR R ONC H, 40(1), 2001, pp. 37-51
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial
Authors: Hortobagyi, GN Ueno, NT Xia, WY Zhang, S Wolf, JK Putnam, JB Weiden, PL Willey, JS Carey, M Branham, DL Payne, JY Tucker, SD Bartholomeusz, C Kilbourn, RG De Jager, RL Sneige, N Katz, RL Anklesaria, P Ibrahim, NK Murray, JL Theriault, RL Valero, V Gershenson, DM Bevers, MW Huang, L Lopez-Berestein, G Hung, MC
Citation: Gn. Hortobagyi et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial, J CL ONCOL, 19(14), 2001, pp. 3422-3433
Pretargeted radioimmunotherapy (PRIT (TM)) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results
Authors: Weiden, PL Breitz, HB Press, O Appelbaum, JW Bryan, JK Gaffigan, S Stone, D Axworthy, D Fisher, D Reno, J
Citation: Pl. Weiden et al., Pretargeted radioimmunotherapy (PRIT (TM)) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results, CANC BIO R, 15(1), 2000, pp. 15-29
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
Authors: Knox, SJ Goris, ML Tempero, M Weiden, PL Gentner, L Breitz, H Adams, GP Axworthy, D Gaffigan, S Bryan, K Fisher, DR Colcher, D Horak, ID Weiner, LM
Citation: Sj. Knox et al., Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer, CLIN CANC R, 6(2), 2000, pp. 406-414
Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and Y-90-DOTA-biotin
Authors: Breitz, HB Weiden, PL Beaumier, PL Axworthy, DB Seiler, C Su, FM Graves, S Bryan, K Reno, JM
Citation: Hb. Breitz et al., Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and Y-90-DOTA-biotin, J NUCL MED, 41(1), 2000, pp. 131-140
Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma
Authors: Krieger, MS Weiden, PL Breitz, HB Press, O DeNardo, GL
Citation: Ms. Krieger et al., Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma, RADIOIMMUNOTHERAPY OF CANCER, 2000, pp. 245-263
Radioimmunotherapy of solid tumors
Authors: Breitz, HB Weiden, PL Beaumier, PL
Citation: Hb. Breitz et al., Radioimmunotherapy of solid tumors, RADIOIMMUNOTHERAPY OF CANCER, 2000, pp. 265-306
Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin
Authors: Breitz, HB Fisher, DR Goris, ML Knox, S Ratliff, B Murtha, AD Weiden, PL
Citation: Hb. Breitz et al., Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin, CANC BIO R, 14(5), 1999, pp. 381-395
Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: Importance of immunocytochemistry
Authors: Gopal, AK Schuetze, SH Maloney, DG Weiden, PL
Citation: Ak. Gopal et al., Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: Importance of immunocytochemistry, BLOOD, 94(7), 1999, pp. 2537-2537
Risultati: 1-9 |